Kadimastem reported the receipt of approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the start of the phase 1/2a clinical trial in ALS patients using its cell therapy AstroRx product. This clinical trial is subject to the approval of Ministry of Health's Supreme Committee for clinical trials in humans, which is expected to convene in the upcoming months. The company stated the trial will include 21 patients and will be conducted by the Department of Neurology of the Hadassah Ein-Kerem Medical Center in Ein-Kerem, a centre in the field of ALS. AstroRx is a cell-based treatment based on astrocytes produced from stem cells. Its unique technology enables large-scale production of the cells according to Good Manufacturing Practices (GMP) standard. The cells will be injected into the ALS patients' spinal fluid using a standard injection procedure, performed routinely in hospitals worldwide.